drugset / Trial / NCT06122181
Study of HS-10384 in Participants of Chinese Postmenopausal Women
RandomizedSequentialDouble-blindTreatment
Summary
A randomized, double-blind, placebo-controlled phase Ib clinical study to evaluate the safety, tolerability and pharmacokinetics characteristics of HS-10384 in Chinese postmenopausal women.
Timeline
- Start
- 2023-11-12
- Primary completion
- 2024-06-30
- Completion
- 2024-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-10384 | Unknown | — | Oral |
Indications
No indication recorded.